Shandong Lukang Pharmaceutical Co., Ltd. Class ASSE: 600789

Announcement on Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of CIGB-814 for Injection

· Issued by Shandong Lukang Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of CIGB-814 for Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis